4 results
The main goal of neoadjuvant therapy should be a pathological complete response (pCR), because pCR more accurately predicts improved patient outcome and prolonged survival. In the present study, pathological response will be evaluated by The Miller…
The primary objective is to estimate the average relative change from baseline in tumoruptake of [89Zr]Zr-BI 765063 (arm A) or [89Zr]Zr-BI 770371 (arm B) upon treatment with BI 765063 (arm A) or BI 770371 (arm B).
To investigate non-inferiority regarding the safety of a 6% HES solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in patients undergoing elective abdominal surgery.
To investigate the maximum tolerated dose (MTD) of BI 907828 in combination with ezabenlimab based on dose limiting toxicities (DLT) during the first treatment cycle and the recommended dose for expansion (RDE), safety and tolerability,…